TABLE 3.

Screening of annulated benzothiazoles on KCa2.3 and KCa3.1 at 1, 10, and 100 μM

The reported numbers are the ratios of slope conductance at −80 mV measured in the presence and absence of drug with 250 nM [Ca²⁺]_i.

			KCa2.3			KCa3.1
			1 μM	10 μM	100 μM	1 μM	10 μM	100 μM
1	Riluzole		1.1 ± 0.3	11.5 ± 4	30 ± 3	6 ± 0.9	30 ± 1.5	30 ± 2
30	SKA-29		1.3 ± 0.2	8.9 ± 1.5	35 ± 4	2.1 ± 0.4	15 ± 4	32 ± 5
31	SKA-44		2.2 ± 0.3	35 ± 7	32 ± 5	16 ± 4	34 ± 3	29 ± 6
32	SKA-49		1.7 ± 0.2	16 ± 2	32 ± 4	3.0 ± 0.6	30 ± 8	36 ± 5
33	SKA-45		7.7 ± 2.7	32 ± 6	Insoluble	30 ± 4	31 ± 3	Insoluble
34	SKA-31		6.3 ± 1.7	34 ± 6	Insoluble	32 ± 2	31 ± 4	Insoluble
35	SKA-20		15 ± 2	30 ± 7	Insoluble	31 ± 2	30 ± 3	Insoluble
36	SKA-21		1.5 ± 0.2	1.5 ± 0.4	Insoluble	N.E.	N.E.	Insoluble
37	SKA-26		N.E.	1.8 ± 0.4	N.D.	N.E.	1.2 ± 0.3	N.D.
38	SKA-50		1.4 ± 0.3	N.E.	N.D.	N.E.	1.5 ± 0.5	N.E.
39	SKA-25		1.9 ± 0.3	4.0 ± 0.7	19 ± 5	4.4 ± 0.6	24 ± 6	35 ± 5
40	SKA-56		N.E.	2.2 ± 2	8 ± 3	1.6 ± 0.5	2.0 ± 1	5 ± 2
41	SKA-30		N.E.	N.E.	N.E.	N.E.	N.E.	N.E.

N.E., no effect; N.D., not determined.